Evidence map›Paper›PMID 41547980›Full record

ArticleScientific reports2026

Influences of formulations and administration routes on docetaxel tissue distribution in mice.

Xiaowei Dong, Tao Zhang, Brijesh Shah, Sung Hun Bae, Jaylen C Mans

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaowei DongDepartment of Pharmaceutical Sciences, College of Pharmacy, University of North Texas System, University of North Texas Health Science Center, Fort Worth, TX, 76107, USA. xiaowei.dong@unthsc.edu.
Tao ZhangDepartment of Pharmaceutical Sciences, SUNY-Binghamton University, Binghamton, NY, USA.
Brijesh ShahDepartment of Pharmaceutical Sciences, College of Pharmacy, University of North Texas System, University of North Texas Health Science Center, Fort Worth, TX, 76107, USA.
Sung Hun BaeDepartment of Pharmaceutical Sciences, SUNY-Binghamton University, Binghamton, NY, USA.
Jaylen C MansDepartment of Pharmaceutical Sciences, College of Pharmacy, University of North Texas System, University of North Texas Health Science Center, Fort Worth, TX, 76107, USA.

Funding

Research Supplements for R35 to Promote Diversity in Health-Related Research, PA-21-071R35GM138225 · NIGMS · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI DONG, XIAOWEI · 2020 to 2025
$2.1M
NIGMS NIH HHS R35 GM138225the National Institutes of General Medical Sciences 1R35GM138225
6 · The paper itself

Abstract

Docetaxel (DTX) is an antimicrotubular chemotherapy drug widely used for treating various cancers. The objective of this study was to evaluate the impact of formulations and administration routes on DTX tissue distribution. The pharmacokinetics and tissue distribution of DTX were assessed using intravenous (IV) injection, intraperitoneal (IP) injection, oral solution, and oral granules in male CD-1 mice. Despite containing DTX crystals, oral DTX granules achieved tissue exposure comparable to that of the oral DTX solution, effectively addressing the poor solubility challenge of DTX while highlighting the need for strategies to enhance permeability in oral DTX formulations. Tissue distribution analysis revealed rapid elimination of DTX from the bloodstream and rapid uptake of DTX into tissue, regardless of formulation or route, emphasizing the importance of tissue concentrations over blood concentrations in evaluating therapeutic efficacy and toxicity for DTX. Notably, DTX exhibited lung selectivity, with oral formulations showing greater lung targeting compared to IP injection. These findings deepen the understanding of DTX tissue distribution and provide critical insights for DTX-based chemotherapy, as well as the development and optimization of novel DTX formulations, particularly for advancing oral DTX treatments and improving cancer therapy.

Indexed as

Antineoplastic AgentsDocetaxelAdministration, OralAnimalsDrug Administration RoutesInjections, IntraperitonealInjections, IntravenousMaleMiceTissue DistributionAntineoplastic AgentsDocetaxelDocetaxelIntraperitoneal injectionIntravenous injectionLung cancerOral formulationTissue distribution

Identifiers

PMID41547980
PMCPMC12816744

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.